Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. | Hu et al. Journal of Hematology Oncology 2011 4 11 http www.jhoonline.Org content 4 1 11 JOURNAL OF HEMATOLOGY ONCOLOGY RESEARCH Open Access A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma 1t 2t 1 1 1 1 3 Jing Hu Gang Zhao Hong-Xia Wang Lei Tang Ying-Chun Xu Yue Ma and Feng-Chun Zhang Abstract Background The objectives of the present study are to investigate the efficacy and safety profile of gemcitabinebased combinations in the treatment of locally advanced and metastatic pancreatic adenocarcinoma LA MPC . Methods We performed a computerized search using combinations of the following keywords chemotherapy gemcitabine trial and pancreatic cancer . Results Thirty-five trials were included in the present analysis with a total of 9 979 patients accrued. The analysis showed that the gemcitabine-based combination therapy was associated with significantly better overall survival OS ORs 1.15 p 0.011 progression-free survival PFS ORs 1.27 p 0.001 and overall response rate ORR ORs 1.58 p 0.001 than gemcitabine monotherapy. Similar results were obtained when the gemcitabine-fluoropyrimidine combination was compared with gemcitabine with the OS ORs 1.33 p 0.007 PFS ORs 1.53 p 0.001 and ORR ORs 1.47 p 0.03 being better in the case of the former. The OS ORs 1.33 p 0.019 PFS ORs 1.38 p 0.011 and one-year survival ORs 1.40 p 0.04 achieved with the gemcitabine-oxaliplatin combination were significantly greater than those achieved with gemcitabine alone. However no survival benefit OS ORs 1.01 p 0.93 PFS ORs 1.19 p 0.17 was noted when the gemcitabine-cisplatin combination was compared to gemcitabine monotherapy. The combinations of gemcitabine and other cytotoxic agents also afforded disappointing results. Our analysis indicated that the ORR improved when patients were treated with the gemcitabine-camptothecin combination rather than gemcitabine alone ORs 2.03 p 0.003 however there were no differences in the OS .
